newsfilter
← Latest News
Business Wire·

Savara Reports Third Quarter 2025 Financial Results and Provides Business Update

-- On Track to Resubmit the Biologics License Application (BLA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) in December and Will Request Priority Review -- -- Expect to Submit the